Axovant reboots with gene therapy deal

Months after a clinical failure in Alzheimer's disease destroyed most of its value, Axovant Sciences Ltd. (NASDAQ:AXON) is seeking a path forward by obtaining rights to a gene therapy for Parkinson's disease.

Oxford BioMedica plc (LSE:OXB) granted Axovant exclusive,

Read the full 388 word article

User Sign In